Background: Peri-operative chemotherapy and surgery is a standard treatment of localised oesophagogastric adenocarcinoma; however, the outcomes remain poor.
introduction
The Medical Research Council's adjuvant gastric infusional chemotherapy (MAGIC) study demonstrated an absolute 13% increase in 5-year survival with the addition of peri-operative ECF [epirubicin, cisplatin and infused 5-fluorouracil (5-FU)] chemotherapy to surgery [1] . These results were supported by a study of peri-operative cisplatin/5-FU, reporting similar benefit [2] . Despite these advances, the outcomes are still poor and thus, there is a real need for investigating new approaches.
In advanced gastric cancer, addition of bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor-A, to cisplatin and capecitabine significantly improved the response rate and progression-free survival (PFS), but not overall survival [3] .
Bevacizumab is associated with uncommon but potentially serious toxic effects including gastrointestinal (GI) perforation, thromboembolism, bleeding, delayed wound-healing and rarely fistula formation and thus, adds additional challenges for a peri-operative regime. Fatal adverse events, in particular haemorrhage, neutropenia and GI perforation, were more common with bevacizumab added to chemotherapy in a metaanalysis of over 10 000 non-gastric cancer patients [4] . In the only phase III study conducted in gastric cancer, there was no increase in treatment-related mortality (3% placebo, 2% bevacizumab) [3] .
Bevacizumab is also associated with an increased risk of cardiac events [5] , and association with cardiac dysfunction was reported in a meta-analysis of advanced breast cancer studies (relative risk 4.74, 95% CI, 1.66-11.18; P = 0.001), although the effect of exposure to anthracyclines and trastuzumab was not evaluated [6] .
Given the potential toxic effects of bevacizumab, ST03 was designed as a randomised phase II/III study, with the first 200 patients contributing to a phase II assessment of safety powered to exclude unacceptable rates of GI perforation and cardiotoxicity. At the time the study was designed, limited data from phase II studies suggested possible additive cardiotoxicity when anthracyclines were combined with bevacizumab, ranging from reversible asymptomatic reduction in left ventricular ejection fraction (LVEF) [7] to grade 3-4 cardiac dysfunction [8] . LVEF monitoring was, therefore, incorporated into the phase II design. Additionally, there were concerns that bevacizumab could adversely affect the surgical outcomes, particularly the risks of delayed wound-healing and bleeding. This report details the phase II study results.
methods study population
The protocol was approved by the Sunderland Research Ethics Committee and the UK Medicines and Healthcare products Regulatory Agency. All participants gave written informed consent. Eligible patients had histologically verified gastric or oesophago-gastric junction (OGJ) adenocarcinoma (Siewert type II or III), stage Ib-IV (T4N1-2M0 only using TNM 6th edition) assessed by computed tomography (CT) scan and laparoscopy. Patients with OGJ tumours also underwent endoscopic ultrasound. Positron emission tomography was carried out according to local practice. World Health Organisation performance status (PS) 0-1, adequate bone marrow, liver and renal function, LVEF ≥ 50% measured by echocardiogram (echo) or multi-gated acquisition (MUGA) scan and absence of proteinuria were required. Patients with cerebrovascular events or myocardial infarction (MI) within 1 year before study entry, uncontrolled hypertension, New York Heart Association ≥class II congestive cardiac failure (CCF), serious cardiac arrhythmia, non-healing wound or ulcer, bleeding diathesis, coagulopathy, active GI inflammatory condition, positive serology for human immunodeficiency virus, hepatitis B or C, known dihydropyrimidine dehydrogenase deficiency, peripheral neuropathy ≥grade 1 or severe tinnitus or receiving specific drugs thought to increase the risk of bleeding or perforation were ineligible.
clinical evaluation
Blood pressure, proteinuria, electrocardiogram, full blood count, serum electrolytes and liver function were assessed every 3 weeks before treatment. CT was repeated before surgery and toxicity recorded using CTCAE (version 3). LVEF was reassessed before surgery and after completion of adjuvant chemotherapy. A further assessment of LVEF was added in a protocol amendment in May 2010, scheduled for 3 months after any absolute drop in LVEF of ≥15% from baseline or to <50% [ Cessation of epirubicin and bevacizumab was initially mandated for falls in the LVEF of ≥15% and/or to <50%. Following cardiological advice sought by the Independent Data Monitoring Committee (IDMC), implemented May 2010, epirubicin and bevacizumab were no longer discontinued for asymptomatic falls within the normal range, while patients with falls below the normal range were started on angiotensinconverting enzyme (ACE) inhibitors. Both the groups of patients underwent additional echo/MUGA 3 months later, and if LVEF was <LLN at this point epirubicin and bevacizumab were discontinued. Additionally, the cardiologist defined a clinically significant decline in LVEF as ≥10% fall to <55% for ECHO or <LLN for MUGA in line with international guidelines [9] .
surgery
For gastric and Siewert type III OGJ tumours, proximal, distal subtotal or total gastrectomy was advised, with excision of at least 15 nodes mandated and formal D2 resection recommended. For type II OGJ tumours, extended gastrectomy or two-phase oesophago-gastrectomy (right or left thoraco-abdominal approach) with a two-field lymphadenectomy was recommended. Minimally invasive surgery was only permitted at sites that had carried out ≥20 previous minimally invasive operations and supplied data on lymph node yields/complication rates and short-term outcomes for review by surgical members of the Trial Management Group.
statistical considerations
Patients were allocated to ECX or ECX-B (1:1) by telephone to the Medical Research Council Clinical Trials Unit. Treatment allocation used minimisation including a random element with predefined stratification factors. The phase II analysis was planned when 200 patients had complete data on preoperative treatment and been followed for ≥6 weeks past the planned surgery date in order to capture serious postoperative complications. The IDMC reviewed data at ∼6-monthly intervals including June 2010, when 200 patients had been randomly assigned and a decision regarding continued cardiac monitoring was required; December 2010, when the phase II cohort was defined as above and the initial analysis of the safety data took place and June 2011 when the extended cardiac monitoring data were reviewed together with updated safety data. The data reported here are taken from the June 2011 data freeze. The primary outcome measure for the phase II study (n = 200) was safety, specifically, rates of gastric and other GI-tract perforations and specific cardiovascular One-sided tests with a 10% significance level were used to screen for unacceptably high-event rates with ECX-B; hence, the results of the specified outcome measures are presented with two-sided 80% CIs. Using Fleming's design, if the true tumour perforation rate with ECX-B is ≤2%, 100 patients treated gives 90% power to exclude rates >7%, at the 10% significance level. For cardiovascular complications, with 100 patients randomly assigned to each arm, an absolute increase of 10% could be detected with 86%-91% power, assuming a rate of 3%-5% with ECX. In addition, GI bleeding events, wound-healing (infection, delayed healing and anastamotic leaks) and treatment completion rates were to be reviewed by the IDMC and these, together with the recruitment rates, would inform the feasibility of the phase III trial ( planned n = 950, including the 200 phase II patients; primary outcome measure overall survival). Release of the perforation and cardiovascular complication rates including LVEF data was pre-specified in the protocol. The IDMC agreed to the release of the other data in this report to reassure participating patients, oncologists and surgeons about the safety and feasibility of adding bevacizumab to ECX. As overall survival is the primary outcome measure for the phase III trial, neither disease-nor treatment-related deaths are detailed in full here but are under routine IDMC review.
results
Between October 2007 and June 2010, 213 patients were randomly assigned, of whom 200 had complete data on preoperative treatment at the December 2010 IDMC review and were, therefore, eligible for the phase II analysis. Baseline demographics (Table 1) are well balanced between the arms. All randomly assigned patients received at least one cycle of ECX ± B and 91/101(90%) ECX and 86 of 99 (87%) ECX-B patients completed three cycles of preoperative treatment. Reasons for early cessation of chemotherapy included toxicity, early surgery, patient choice and other (including disease progression) (Figure 1 ). Of 91 ECX and 86 ECX-B patients who completed preoperative chemotherapy, 81 ECX (89%) and 76 ECX-B (88%) patients proceeded to surgery. Minimally invasive techniques were used in 23 patients (15%). Of 86 patients who completed preoperative ECX-B, bevacizumab was delivered in 95% of cycles received.
toxicity and notable events
The primary outcome measure rates for phase II and other protocol-defined notable events are summarised in Table 2 . Two ECX patients and one (1.0%, 80%CI 0.1%-3·9%) ECX-B patient experienced a gastric perforation at the primary site. One ECX patient had a gastric perforation 10 days postoesophagectomy. VTEs occurred at similar rates in both the arms. ATEs (MI/CVA) were more frequent with bevacizumab (1 ECX, 5 ECX-B). Wound-healing complications defined as wound infections (8 ECX, 6 ECX-B), delayed wound-healing including wound dehiscence and delayed wound-healing without documented infection (2 ECX, 4 ECX-B) and suture line leaks (5 ECX, 5 ECX-B) and GI haemorrhages (4 ECX, 1 ECX-B) were not increased by bevacizumab.
Other frequently occurring (≥10%) and/or grade ≥3 adverse events (summarised in Table 3 ) are similar in the two groups. Following the review of febrile neutropenia SAEs, an urgent safety amendment was passed in February 2010 to mandate nadir neutrophil count (around day 10) testing during cycle 1 in both the arms and prophylactic granulocyte colony stimulating factor for all cycles for any patients with grade 3-4 neutropenia at that nadir count (delivered without interruption of capecitabine).
cardiac toxicity
At the data freeze for the IDMC meeting in June 2010, 212 patients had been randomly assigned and LVEF data at baseline and ≥1 additional time point were available for 100 patients. The IDMC recommended that LVEF monitoring should continue beyond the planned 200 patients. The data were reviewed again at the IDMC meetings in December 2010 and June 2011. In June 2011, 397 patients had been randomly assigned, 246 patients had LVEF data at baseline and ≥1 additional time point. Reviewing these data, the IDMC recommended that LVEF monitoring could cease, and that the safety data presented here could be released. At that time, 175 (Table 4 , bottom row). Of the 8 ECX and 13 ECX-B patients considered to have had a significant fall in LVEF, 2 ECX and 4 ECX-B patients had a LVEF of <50% at the end of postoperative chemotherapy, all recovered to ≥50% 3 months later. One patient experienced CCF in the context of sepsis, MI and LV thrombus (LVEF 30% recovered to 50% 3 months later). At a median 22 months follow-up from randomisation, no symptoms of CCF were recorded in the remaining 20 patients with a clinically significant asymptomatic fall in the LVEF. In deciding whether LVEF monitoring could be discontinued, the IDMC balanced these observations against the potential harm from protocoldirected reductions in therapy driven by the LVEF monitoring, given that this is not part of routine administration of peri-operative ECX in the UK, and advised that LVEF monitoring should be discontinued. LVEF assessment before entry into the study remains. Four of the 99 ECX + B patients and 1 of 101 ECX patients had at least one cardiac event according to the protocol definition [difference = 3.0% 80%CI (0.2%-5.8%)] of whom all experienced MI. In three patients where the event was grade 5 (all ECX-B), coronary artery atheroma was noted at postmortem examination, which had been asymptomatic in two. In the third patient, coronary artery disease was diagnosed during cycle 1 and ATEs occurred following disease progression during oesophageal stent insertion, 4 months after the last administration of bevacizumab. All had risk factors for coronary disease including hypertension, type II diabetes and/ or history of smoking; one had uncontrolled hypertension at (BP 168/73) contrary to study eligibility criteria. discussion This paper demonstrates that bevacizumab can be safely added to ECX chemotherapy before a potentially curative resection for gastric and OGJ adenocarcinoma. The low incidence of GI perforation is encouraging, as patients had the primary tumour in situ, a probable risk factor for this event [10] . In colorectal cancer studies evaluating bevacizumab, the rates of perforation are reported to be higher at 3% to 4% when the primary tumour is in situ [11] [12] [13] [14] compared with 0.3% reported in the adjuvant setting [15] . At the time when this study was developed, a phase II study of cisplatin, irinotecan and bevacizumab (15 mg/kg) for advanced gastric cancer reported perforations in 2 of 47 patients, with one further near- perforation (6%). However, the larger AVAGAST trial [3] where bevacizumab was administered at a lower dose of 7.5 mg/kg, as in ST03, only reported perforation in 2% of patients receiving chemotherapy plus bevacizumab.
A recent meta-analysis of published phase III studies of bevacizumab demonstrated an increased incidence of fatal adverse events with bevacizumab added to platinum or taxanes (3.3% compared with 1.0%, relative risk 3.49; 95% CI, 1.82-6.66) irrespective of the primary tumour site or bevacizumab dose [4] . This is not consistent with the rate of treatmentrelated deaths in AVAGAST (3% with chemotherapy plus placebo, 2% with chemotherapy and bevacizumab), despite the use of platinum [3] .
The rate of grade ≥4 VTE with ECX-B in this study contrasts with a meta-analysis demonstrating significantly increased risk with bevacizumab in advanced solid tumours (relative risk 1.33, 95% CI, 1.13-1.56; P < 0.001) [16] . However, this analysis was not corrected for the use of central venous access devices, which is associated with VTE in advanced gastric cancer [17] , and may have confounded the results. In the AVAGAST trial, grade 3-5 VTE was reported in 9% of patients receiving placebo and 6% receiving bevacizumab ( pulmonary embolism in 5% and 3%, respectively) [3] . In contrast, in two earlier phase II studies of chemotherapy plus bevacizumab (15 mg/kg), grade 4 thromboembolism was reported in 19% with irinotecan and cisplatin [18] and 23% with a modified DCF regimen [19] , possibly reflecting more thrombogenic chemotherapy regimens and the higher bevacizumab dose. Oxaliplatin is associated with a lower rate of thromboembolism than cisplatin [17] ; however, these results were not available at the time ST03 was planned.
Bevacizumab (15 mg/kg) has been combined with epirubicin at a cumulative dose of 360 mg/m 2 as neoadjuvant therapy for localised breast cancer with LV changes of ≥10% to <50% reported rarely in 1948 randomly assigned patients Table 3 . Grade ≥3 or frequently occurring toxicities (≥10%) during neo-adjuvant chemotherapy Serious or frequently occurring adverse events (≥10%) ECX (n = 101) ECX-B (n = 99) Thrombocytopaenia  13  13  1  1  15  15  0  0  Neutropaenia  35  34  24  24  29  29  30  30  Febrile neutropaenia  --5  5  --5  5  Diarrhoea  27  27  6  6  28  28  7  7  Stomatitis  40  40  2  2  39  39  3  3  Hand-foot syndrome  35  35  7  7  30  30  9  9  Nausea  69  68  6  6  60  60  7  7  Vomiting  34  34  4  4  34  34  4  4  Peripheral neuropathy  19  19  0  0  15  15  0  0  Chest pain  2  2  0  0  4  4  3  3  Renal impairment  10  10  0  0  9  9  1  1  T a s t e  3 6  3 6  1  1  3 0  3 0  1  1  Anorexia  32  32  6  6  34  34  4  4  Lethargy  70  70  10  10  71  71  12  12  Alopecia  64  64  0  0  57  57  0  0 This includes data on any grade ≥3 toxicity or any toxicity that has occurred in >10% of patients during the preoperative treatment. Includes data on all Phase II primary outcomes with the addition of other notable events that have been reported which require expedited reporting.
original articles Annals of Oncology (1% with bevacizumab versus 0.2% without) [20] . Our results, however, showed asymptomatic falls in LVEF occurring in both the groups of patients but more frequently in those receiving bevacizumab. No cases of CCF were attributed to these falls despite extended monitoring and the LVEF improved once the therapy was discontinued, consistent with other reports [7, 8] .
Of note, exposure to bevacizumab with preoperative therapy was limited to three doses; therefore, further analysis of LVEF once this cohort have completed all planned treatment is warranted.
ATEs appeared more frequent with bevacizumab which is consistent with previous reports [5] , and is being closely monitored by the IDMC. Additionally, the study eligibility criteria have been amended to define 'uncontrolled hypertension' as blood pressure >140/90 mmHg.
Possibly due to the 8-9 week delay between the final dose of bevacizumab and the surgery, no increase in wound-healing complications was observed, and the rate of anastamotic leaks was similar. This is in contrast to a previous analysis of two studies of bevacizumab in colorectal cancer patients undergoing unplanned major surgery, where more grade 3-4 wound-healing events were observed in patients receiving bevacizumab, whether the surgery was carried out within 30 days, or 31-60 days from the last dose [21] .
The lack of benefit seen in the adjuvant C-08 [22] and AVANT studies [23] , with evidence of a negative impact of bevacizumab on survival in the latter, has called into question the role of bevacizumab in patients with completely resected disease. A pre-clinical study has reported increased spontaneous metastases and reduced survival in mice with severe combined immunodeficiency dosed with sunitinib following the removal of primary human breast cancer and melanoma xenografts [24] , but we are not aware of similar data with bevacizumab. In contrast, in maximally debulked ovarian cancer, adjuvant bevacizumab delivered in combination with chemotherapy improves PFS [25, 26] and appears most beneficial in patients at highest risk of relapse [26] , especially when delivered with a period of maintenance bevacizumab monotherapy [25] . However, these are patients with microscopic and often macroscopic residual disease. The results from the AVAGAST study showing improved response rates and PFS [3] are encouraging for ST03 as it can be hypothesised that increased response rates will increase the pathological response and R0 resection rates. The updated results from the UK OEO2 trial and the US RTOG 8911 trial evaluating neoadjuvant chemotherapy in oesophageal cancer both show that survival correlates with R0 resection [27, 28] . While the toxicity observed in this initial cohort of ST03 patients is acceptable, ultimately, it will need to be balanced against efficacy and health-related quality-of-life data at the final phase III analysis; expected late 2014.
conclusions
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